2013
Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes
Sherr J, Xing D, Ruedy KJ, Beck RW, Kollman C, Buckingham B, White NH, Fox L, Tsalikian E, Weinzimer S, Arbelaez AM, Tamborlane WV, Network F. Lack of Association Between Residual Insulin Production and Glucagon Response to Hypoglycemia in Youth With Short Duration of Type 1 Diabetes. Diabetes Care 2013, 36: 1470-1476. PMID: 23288858, PMCID: PMC3661789, DOI: 10.2337/dc12-1697.Peer-Reviewed Original ResearchConceptsMixed meal tolerance testΒ-cell functionResidual β-cell functionC-peptide levelsGlucagon responseT1D subjectsHypoglycemic clampPlasma glucagonPg/Endogenous β-cell functionPlasma C-peptide levelsAbsent glucagon responsesNondiabetic young adultsResidual insulin productionC-peptide responseNondiabetic control subjectsType 1 diabetesLack of associationT1D durationIncremental increaseControl subjectsTolerance testHypoglycemiaInsulin productionType 1
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisCharacteristics of patientsC-peptide levelsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab